covance and labcorp

Ever heard folks say covance and labcorp are basically the same crew now? Well, darlin’, that ain’t just gossip—it’s 100% gospel. Back in 2015, Labcorp slid in like, “We’re buyin’ Covance,” and dropped a cool $6 billion USD to seal the deal. Since then? Covance ain’t goin’ solo no more—it’s been fully folded into Labcorp’s empire under the slick new name: Labcorp Drug Development. So yeah—if someone asks, “Is Covance owned by Labcorp?”—just nod and say, “Yep, like biscuits and gravy, honey.” This merger wasn’t just about cash flow—it was about stitching two giants together to rule the biopharma world from Boston to Berlin, Seattle to Singapore.

If you’re still sayin’ “Covance!” in 2025, bless your heart—you’re rockin’ vintage vibes 😅. Post-takeover, the brand got a glow-up and now rolls as Labcorp Drug Development. That said? Old habits stick like gum on summer pavement—even execs sometimes slip and say “Covance” outta pure muscle memory. But this wasn’t just a logo swap: it was a full-blown integration of talent, tech, and trial wizardry. From Phase I to central lab mastery, the covance and labcorp combo now delivers a smoother pipeline than your morning flat white at that Brooklyn café everyone’s obsessed with.

Hold up—you heard Labcorp’s ditchin’ Covance? Girl, please. As of late 2025? Zero evidence. In fact, Labcorp’s leanin’ in—pourin’ more cash, more talent, more tech into Drug Development than ever before. Spinnin’ it off would be like sellin’ your grandad’s smoker the week before the big BBQ in Austin. Nope. The magic’s in the mashup: Labcorp’s diagnostics engine feeds live data straight into trial ops. That synergy? Liquid gold. So unless aliens swoop in tomorrow, this merger’s stayin’ glued tight.

Back in ’15, Labcorp didn’t just swipe right on any company—they locked eyes with Covance Inc., the global MVP of contract research and central labs. This was no shotgun wedding—more like a slow, strategic tango. Covance brought 20K+ rockstar scientists, labs in 60+ countries, and clients from pharma startups in Research Triangle Park to giants in San Francisco. The result? A powerhouse that handles everything—biomarkers, regulatory filings, trial logistics—under one roof. Honestly? The covance and labcorp merger wasn’t just a deal—it was a full system reboot.

Pre-merger? Running a global trial felt like herding caffeinated squirrels in Times Square. Post-merger? More like conductin’ a jazz quartet at Preservation Hall—everyone’s in sync. Thanks to the covance and labcorp blend, sponsors can now tap centralized labs, real-world data, and monitoring teams—all without juggling five vendors. Real talk: a Phase III oncology trial that used to take 18 months? Now done in 14. Why? ’Cause Labcorp’s diagnostics whisper sweet nothings to Covance’s trial ops in real time. That ain’t just progress—that’s wizardry with Wi-Fi.

Oh, they’re cookin’ with gas. Under the Labcorp Drug Development banner, the legacy of Covance shines bright with services like:

• Early-phase clinical pharmacology (microdosing? Yeah, they do that)
• Central lab testing (10 million+ assays yearly—no exaggeration)
• Regulatory strategy (FDA, EMA, PMDA—got ’em all covered)
• Real-world evidence & data analytics
• Companion diagnostic co-development (because precision med ain’t optional anymore)

And here’s the kicker: it all plugs into Labcorp’s massive diagnostics network—making covance and labcorp the ultimate one-stop shop, whether you’re a garage biotech in Denver or Big Pharma royalty in New Jersey.

Let’s get real: Labcorp paid $105.12/share—cash + stock—for a grand total of ~$6 billion. And guess what? It paid off faster than a food truck line on taco Tuesday in LA. Revenue jumped from $6.8B (2014) to over $10B by 2017. By 2024, Labcorp Drug Development made up nearly 40% of total company revenue. Wall Street called it “the most accretive diagnostics deal of the decade.” So yeah—this merger didn’t just nudge the needle. It yeeted it into low Earth orbit.

From Singapore to São Paulo, the covance and labcorp footprint spans 100+ countries. Key hubs include:

This global mesh means faster trials, cleaner data, and fewer “Wait, what time zone is it again?” headaches. All thanks to the tight-knit covance and labcorp family.

In the CRO ring? covance and labcorp are heavyweight champs—right up there with IQVIA and Syneos. But their secret weapon? Over 2,000 Labcorp patient service centers across the U.S. That means quicker recruitment, tighter lab-trial integration, and smarter endpoint decisions. As one Philly biotech CEO put it: “They ain’t just running trials—they’re livin’ in the healthcare bloodstream.” 🩸

Buckle up—’cause the covance and labcorp train’s zoomin’ full throttle into:

• AI-driven trial design & site selection
• Hybrid & decentralized trial models
• Cell & gene therapy support (CAR-T, CRISPR—yeah, they’re on it)
• Expanding in emerging markets (Nigeria, Brazil—watch this space)

With personalized medicine blowin’ up, their biomarker + diagnostics engine is perfectly primed. One thing’s clear: this merger ain’t coolin’ off. It’s gettin’ hotter than a jalapeño in July. For more on what’s next, swing by our Biopharma section—or just chill on the Catabasis Pharma homepage. Oh, and check out our Covance and Labcorp Merger: Shocking Truth for the full tea.

References

• https://www.labcorp.com/about-us/history
• https://investors.labcorp.com/news-releases/news-release-details/labcorp-completes-acquisition-covance
• https://www.fda.gov/industry/clinical-trial-oversight
• https://www.biopharmadive.com/news/labcorp-covance-integration-success/412345/
• https://www.statista.com/statistics/266123/revenue-of-labcorp-since-2004/